Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz

BMC Research Notes

Simin Dashti-Khavidaki⁴  Alireza Abdollahi¹  Sirous Jafari⁵  Hossein Khalili²  Maryam Etminani-Esfahani³ 

[1] Department of pathology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran;Department of Clinical Pharmacy, Faculty of pharmacy, Tehran University of Medical Sciences, Enghelab Ave, 1417614411, P.O.Box:14155/6451, Tehran, Iran;Clinical Pharmacist, Department of Clinical Pharmacy, Faculty of Pharmacy, Ahvaz University of Medical Sciences, Tehran, Iran;Clinical Pharmacist, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran;Iranian Research Center for HIV/AIDS, Department of Infectious Diseases, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

关键词: Vitamin D;    Efavirenz;    HIV;   

Others  :  1166477
DOI  :  10.1186/1756-0500-5-204

 received in 2012-01-11, accepted in 2012-04-11,  发布年份 2012

【 摘 要 】

Background

It was reported that antiretroviral drugs such as efavirenz can increase the catabolism of vitamin D in HIV infected individuals. We have not found any study that evaluated effects of vitamin D supplementation on the bone specific biomarkers in HIV positive patients under treatment with antiretroviral regimen containing efavirenz.

Findings

Vitamin D deficiency was detected in 88.4 % of included patients. Baseline osteocalcin, but not collagen telopeptidase, serum levels were lower than normal range in all of these individuals. Both bone biomarkers’ concentrations increased significantly (p < 0.001 for both of them) after supplementation of vitamin D and it was more predominant for osteocalcin.

Conclusion

In the HIV-infected patients under treatment with efavirenz, vitamin D deficiency is prevalent. After supplementation with single dose of 300,000 IU vitamin D in this population, the activation of osteoblasts and osteoclasts stimulates bone formation and resorption respectively with favorable bone formation without any adverse event. Significant percent of HIV infected individuals are vitamin d deficient that could benefit from vitamin D supplementation.

【 授权许可】

   
2012 Etminani-esfahani et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]The Joint United Nations Programme on AIDS (UN-AIDS): AIDS Epidemic Update. Geneva: World Health Organization; 2009.
• [2]Overton ET, Yin MT: The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations. Curr Infect Dis Rep 2011, 13:83-93.
• [3]Gutiérrez F, Masiá M: The role of HIV and antiretroviral therapy in bone disease. AIDS Rev 2011, 13:109-118.
• [4]Ofotokun I, Weitzmann MN: HIV and bone metabolism. Discov Med 2011, 11:385-393.
• [5]Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G: Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004, 48:39-48.
• [6]Hoy J: Bone, fracture and frailty. Curr Opin HIV AIDS 2011, 6:309-314.
• [7]Seibel MJ: Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005, 26:97-122.
• [8]Hadjidakis DJ, Androulakis II: Bone remodeling. Ann N Y Acad Sci 2006, 1092:385-396.
• [9]Stone B, Dockrell D, Bowman C, McCloskey E: HIV and bone disease. Arch Biochem Biophys 2010, 503:66-77.
• [10]Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, Post FA: Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010, 31:1923-1928.
• [11]Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, Bush T, Brooks JT: Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011, 52:396-405.
• [12]Pasquet A, Viget N, Ajana F, de la Tribonniere X, Dubus S, Paccou J, Legroux-Gérot I, Melliez H, Cortet B, Yazdanpanah Y: Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? AIDS 2011, 25:873-874.
• [13]Huang J, Meixner L, Fernandez S, McCutchan JA: A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009, 23:51-57.
• [14]Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, Hasson H, Danise A, Guffanti M, Lazzarin A, Rubinacci A: Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 2005, 6:145-150.
• [15]Haskelberg H, Carr A, Emery S: Bone turnover markers in HIV disease. AIDS Rev 2011, 13:240-250.
• [16]Seibel MJ: Biochemical markers of bone turnover: part II: Clinical Applications in the Management of Osteoporosis. Clin Biochem Rev 2006, 27:123-138.
• [17]Vieth R: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999, 69:842-856.
• [18]Premaor MO, Scalco R, da Silva MJ, Froehlich PE, Furlanetto TW: The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit. J Bone Miner Metab 2008, 26:603-608.
• [19]Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ, Rainbow SJ, Berry JL, Griffiths CJ: A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007, 176:208-213.
• [20]Sakalli H, Arslan D, Yucel AE: The effect of oral and parenteral vitamin D supplementation in the elderly: a prospective, double-blinded, randomized, placebo-controlled study. Rheumatol Int 2011, 2:1-2. May 10. [Epub ahead of print]
• [21]Boyce BF, Xing L: Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008, 473:139-146.
• [22]Vega D, Maalouf NM, Sakhaee K: The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007, 92:4514-4521.
• [23]Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K: c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest 2006, 116:528-535.
• [24]Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U, O'Loughlin PD, Nicholson GC, Briffa KH, Eisman JA, Gardiner EM: Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res 2006, 211:618-626.
• [25]Jorde R, Sneve M, Torjesen PA, Figenschau Y, Hansen JB, Grimnes G: No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year. Nutr J 2010, 7:1.
• [26]Barkhordarian A, Ajaj R, Ramchandani MH, Demerjian G, Cayabyab R, Danaie S, Ghodousi N, Iyer N, Mahanian N, Phi L, Giroux A, Manfrini E, Neagos N, Siddiqui M, Cajulis OS, Brant XM, Shapshak P, Chiappelli F: Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective. Patholog Res Int 2011, 2011:359242. Epub 2011 May 21
• [27]Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R: Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566-575.
• [28]Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962-970.